Great Lakes Advisors LLC Has $3.30 Million Stake in Alphatec Holdings, Inc. $ATEC

Key Points

• Great Lakes Advisors LLC reduced its stake in Alphatec Holdings, Inc. by 14.2%, owning 325,227 shares worth $3.3 million after selling 53,960 shares.
• Alphatec reported a quarterly revenue of $185.54 million, surpassing analyst estimates, and achieved a positive EPS of $0.02, compared to a loss of ($0.29) EPS from the previous year.
• Several analysts upgraded Alphatec's stock to a buy rating, with the average price target set at $18.50, indicating a bullish outlook on the company's prospects.

Great Lakes Advisors LLC lessened its stake in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 14.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 325,227 shares of the medical technology company's stock after selling 53,960 shares during the quarter. Great Lakes Advisors LLC owned about 0.22% of Alphatec worth $3,298,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ATEC. Nuveen LLC bought a new position in Alphatec during the 1st quarter valued at $135,874,000. Vanguard Group Inc. boosted its stake in Alphatec by 0.8% during the first quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock valued at $60,990,000 after buying an additional 45,792 shares in the last quarter. American Century Companies Inc. grew its holdings in Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company's stock worth $59,117,000 after acquiring an additional 840,974 shares during the period. Royal Bank of Canada raised its position in Alphatec by 10.8% in the first quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company's stock worth $35,773,000 after acquiring an additional 342,656 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its holdings in Alphatec by 78.4% in the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock valued at $23,730,000 after acquiring an additional 1,136,330 shares during the last quarter. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Stock Down 2.4%

Shares of ATEC traded down $0.37 during midday trading on Friday, reaching $15.26. 1,736,713 shares of the stock were exchanged, compared to its average volume of 1,980,824. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -13.50 and a beta of 1.02. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $16.70. The firm has a 50 day simple moving average of $13.85 and a 200-day simple moving average of $12.09.

Alphatec (NASDAQ:ATEC - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business had revenue of $185.54 million during the quarter, compared to analyst estimates of $178.85 million. During the same quarter in the previous year, the business earned ($0.29) EPS. Alphatec's quarterly revenue was up 27.5% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. Research analysts forecast that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

ATEC has been the topic of several recent research reports. Lake Street Capital raised shares of Alphatec to a "buy" rating and set a $18.00 price objective on the stock in a research note on Monday, June 16th. Wall Street Zen upgraded shares of Alphatec from a "hold" rating to a "buy" rating in a research report on Sunday, September 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $20.00 price objective on shares of Alphatec in a research report on Friday, August 1st. Finally, Barclays reissued an "overweight" rating and set a $22.00 price objective (up from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $18.50.

Insiders Place Their Bets

In other Alphatec news, CEO Patrick Miles sold 300,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $15.73, for a total transaction of $4,719,000.00. Following the completion of the sale, the chief executive officer directly owned 5,564,078 shares in the company, valued at $87,522,946.94. This represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Scott Lish sold 6,323 shares of the firm's stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $16.01, for a total value of $101,231.23. Following the completion of the sale, the chief operating officer directly owned 658,707 shares in the company, valued at approximately $10,545,899.07. This represents a 0.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 546,057 shares of company stock valued at $8,326,072 in the last three months. Company insiders own 20.90% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.